Khaled Musallam: De-LIGHT Study Reveals Age-Related Multisystem Morbidity in β-Thalassemia
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Haematologica, adding:
“Pleased to share our new study out today in Haematologica:
‘β-thalassemia as a progressive disease: age-related morbidity in the de-LIGHT study.’
Our findings highlight an important shift in how we think about β-thalassemia: as patients live longer, multisystem morbidity progressively accumulates across the lifespan, in both transfusion-dependent and non-transfusion-dependent disease.
These data reinforce the importance of lifelong disease control, age-adapted surveillance, and (hopefully when available) earlier use of disease-modifying approaches before irreversible complications develop.”
Title: β-thalassemia as a progressive disease: age-related morbidity in the de-LIGHT study
Authors: Khaled M. Musallam, Angela Vitrano, Alessandro Inzerillo, Rosario Di Maggio, Rita Barone, Antonino Giangreco, Maria Concetta Renda, Emanuela Fecarotta, Antonio Troia, Antonino Giambona, Giovan Battista Ruffo, Efthymia Vlachaki, Theodora M. Venou, Paolo Ricchi, Brunella Ziello, Marilena Serra, Elena Colizzi, Filomena Longo, Martina Culcasi, Aurelio Maggio

Find more posts featuring Khaled Musallam on Hemostasis Today.
-
Nov 19, 2026, 16:27263 PolyU Students and Staff Unite to Donate Blood – Hong Kong Red Cross Blood Transfusion Service
-
Nov 19, 2026, 16:16Billy Otieno: The Future of Blood Donation Lies Beyond Collection
-
Nov 19, 2026, 15:58Hema Goyal: Hematocon 2026 Bringing Together Knowledge, Innovation and Excellence in Hematology
-
Nov 19, 2026, 15:44Chukwuemeka Amarachi: Understanding Complex Blood Grouping Beyond Routine ABO And RhD Typing
-
Nov 19, 2026, 14:19Long-Read Sequencing Is Closing Diagnostic Gaps in Inherited Bleeding Disorders
-
Nov 19, 2026, 13:36Raja Prince: Protein S Silencing and the Future of Hemostatic Therapy
-
Nov 19, 2026, 13:26M. Sekip Altunkan: The Thrombotic Risk of Andexanet Alfa
-
Nov 19, 2026, 13:18Felice Gragnano: Personalizing Antiplatelet Therapy After PCI
-
Nov 19, 2026, 13:11When Postpartum Warning Signs Are Ignored – National Blood Clot Alliance